Rezpegaldesleukin was investigated as a treatment for adults with moderate-to-severe atopic dermatitis in the REZOLVE-AD clinical development programme. The trial reported here focused on the 16-week induction period and was conducted to evaluate the investigational agent in a controlled, randomized setting. The PubMed entry emphasizes the study name and context but the excerpt available does not provide detailed clinical rationale, mechanism of action, or preclinical data.
The REZOLVE-AD induction study is described in the PubMed record as an international, double-blind, placebo-controlled, randomized phase 2b trial with a 16-week induction period. These descriptors indicate a multicentre clinical trial intended to evaluate efficacy and safety signals in a broader patient population than typical phase 2a studies. The PubMed summary available here specifies the design elements (international, randomized, double-blind, placebo-controlled) and duration of the induction period (16 weeks). The excerpt does not include further methodological detail such as randomization ratios, stratification factors, or statistical analysis plans.
The publication lists a broad and international authorship team with named academic and clinical investigators from multiple countries and institutions. Lead and contributing authors include clinicians and researchers affiliated with dermatology departments and clinical research centres across the USA, Canada, Europe, and Australia, among others. The PubMed entry also identifies contributors employed by the sponsor or manufacturer (Nektar Therapeutics), and enumerates the REZOLVE-AD Study Investigators and many collaborating site investigators. This extensive list reflects a large, multi-centre network used to perform the study.
The PubMed excerpt identifies the investigational agent as rezpegaldesleukin and that the dataset covers a 16-week induction period. The public abstract text included here does not specify dosing regimens, route of administration, frequency, comparator placebo characteristics, or concomitant allowed treatments. Those intervention details were not reported in the visible PubMed excerpt and must be obtained from the full Lancet article or supplementary materials.
The record on PubMed indicates the study type and induction duration but does not enumerate the primary or secondary endpoints in the excerpt provided. There is no listing in this excerpt of efficacy measures (for example, clinician-reported disease severity scores, patient-reported outcomes, or time-to-response metrics) nor of the specific statistical endpoints or hierarchies. Information on how efficacy was defined and measured, or on pre-specified safety endpoints, was not included in the PubMed snippet available here.
The PubMed summary identifies the paper title as reporting the “final results from the 16-week induction period,” but the excerpt accessible in this record does not contain the trial results themselves. No numerical efficacy outcomes, responder rates, treatment differences, p values, confidence intervals, or other efficacy findings are presented in the visible portion of the PubMed entry. For complete results, including primary and secondary endpoint outcomes and any subgroup analyses, consult the full text of the Lancet article or the publisher’s site.
Although safety monitoring is an expected component of phase 2b randomized trials, the PubMed excerpt does not report any safety data, adverse event frequencies, serious adverse events, or laboratory findings. The provided record does not include descriptions of tolerability, dose-limiting toxicities, or withdrawals related to adverse events. These data appear in the full article and are not reproduced in this PubMed summary.
The report is published in Lancet, cited as . 2026 Aug 29;408(10557):833-846, DOI 10.1016/S0140-6736(26)01143-8, with electronic publication on Aug 22, 2026. The PubMed entry includes a link to Elsevier Science full text options. The author list is extensive and includes academic dermatologists and sponsor-affiliated contributors. The PubMed page provides standard bibliographic metadata and full author and collaborator lists.
This PubMed excerpt provides study identification, authorship, and trial design descriptors but omits key clinical content. Specifically, the following were not reported in the visible PubMed content: participant numbers and baseline characteristics, detailed inclusion/exclusion criteria, dosing regimen and administration details, primary and secondary endpoint definitions, statistical analysis methods, numerical efficacy results, safety and adverse event data, and subgroup analyses. Because the PubMed summary here is truncated, readers seeking clinical outcomes, safety profiles, and full methodological transparency should access the full Lancet article or supplementary materials.
Note: All statements above are limited to the content presented in the PubMed entry excerpt available here. Numerical outcomes, efficacy conclusions, and safety findings were not included in this source excerpt and therefore are not reported in this summary.